Synonym
Eprodisate Free Base; 1,3-Propanedisulfonic acid; Propane-1,3-disulfonate; Eprodisato
IUPAC/Chemical Name
propane-1,3-disulfonic acid
InChi Key
MGNVWUDMMXZUDI-UHFFFAOYSA-N
InChi Code
InChI=1S/C3H8O6S2/c4-10(5,6)2-1-3-11(7,8)9/h1-3H2,(H,4,5,6)(H,7,8,9)
SMILES Code
OS(=O)(CCCS(=O)(O)=O)=O
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
204.21
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Manenti L, Tansinda P, Vaglio A. Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? Expert Opin Pharmacother. 2008 Aug;9(12):2175-80. doi: 10.1517/14656566.9.12.2175. PMID: 18671471.
2: Manenti L, Tansinda P, Vaglio A. Eprodisate in AA amyloidosis. N Engl J Med. 2007 Sep 13;357(11):1153; author reply 1153-4. doi: 10.1056/NEJMc071922. PMID: 17855678.
3: Dember LM, Hawkins PN, Hazenberg BP, Gorevic PD, Merlini G, Butrimiene I, Livneh A, Lesnyak O, Puéchal X, Lachmann HJ, Obici L, Balshaw R, Garceau D, Hauck W, Skinner M; Eprodisate for AA Amyloidosis Trial Group. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med. 2007 Jun 7;356(23):2349-60. doi: 10.1056/NEJMoa065644. PMID: 17554116.
4: Dasgupta NR, Cummings OW, Phillips CL, Benson MD. AA cardiomyopathy. Amyloid. 2017 Mar;24(sup1):138-139. doi: 10.1080/13506129.2017.1284056. PMID: 28434308.
5: Rumjon A, Coats T, Javaid MM. Review of eprodisate for the treatment of renal disease in AA amyloidosis. Int J Nephrol Renovasc Dis. 2012;5:37-43. doi: 10.2147/IJNRD.S19165. Epub 2012 Feb 24. PMID: 22427728; PMCID: PMC3304340.
6: Rule AD, Leung N. Eprodisate slows the progression of renal disease in patients with AA amyloidosis. Nat Clin Pract Nephrol. 2007 Nov;3(11):592-3. doi: 10.1038/ncpneph0615. Epub 2007 Sep 18. PMID: 17876351.
7: Zdrojewski Z. Amyloidoza w chorobach reumatycznych [Amyloidosis in rheumatic diseases]. Ann Acad Med Stetin. 2010;56 Suppl 1:7-15. Polish. PMID: 21365934.
8: Blank N, Lorenz HM. Diagnostik und Therapie der AA-Amyloidose [Diagnostics and therapy of AA amyloidosis]. Pathologe. 2009 May;30(3):219-25. German. doi: 10.1007/s00292-009-1140-5. PMID: 19333604.
9: Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Apr;29(3):231-45. PMID: 17520107.
10: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Apr;30(3):231-51. PMID: 18597009.
